Cancer statistics, 2025
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes u…
Related Articles
New Tool Can Help Improve Health Equity in Cancer Centers : Oncology Times
An abstract is unavailable.
Distinctions Between Alteration Types, Therapeutic Classes Could Drive Optimal Treatment Selection in HER2-Mutant NSCLC
Nicolas Girard, MD, compares the predictive value, mechanisms of action, and safety or efficacy profile of HER2-targeted TKIs vs ADCs in NSCLC.
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult…
FDA Approves Dato-DXd in Metastatic HR+/HER2– Breast Cancer
Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.
Program
Explore the program for the AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia, held March 7-9, 2025, in San Diego.
FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer
The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.
A metabolic pathway for improving adoptive cellular therapy
In this issue of Cancer Cell, Qiu et al. use single-cell metabolic analysis to identify reduced mannose metabolism as a previously unknown feature of exhausted T cells.…
Plasma cell and cancer stem cell crosstalk in glioblastoma
Plasma cells (PCs) are the main producers of antibodies and have context-dependent roles in tumor immunity. In this issue of Cancer Cell, Gao et al. report…
FDA approves acalabrutinib with bendamustine and rituximab for previously untreated MCL
On January 16, 2025, the U.S. Food and Drug Administration (FDA) approved acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with bendamustine and rituximab…
One Form to “Rule” Them All (and in the TM Bind Them) | SWOG
Our translational research generally builds on resources from our clinical trials, just as our clinical studies build on information learned from our translational research. We’re…
